Hello,
Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and today in healthcare news:
- The 5 vaccines Moderna's working on next – including a combo shot;
- Patients say the US is dragging its feet on a promising ALS treatment;
- What Biden's infrastructure plan might mean for the home-care industry.
If you're new to this newsletter, sign up here. Comments, tips? Email me at [email protected] or tweet @lydiaramsey125. Let's get to it…
First: Please join us today at 11 a.m. ET for a free live event on J&J's COVID-19 vaccine and blood clots.
Deputy editor Zach Tracer will be chatting with reporters Dr. Catherine Schuster-Bruce and Aria Bendix about the latest developments after US officials recommended pausing the vaccine's rollout.
The latest: the J&J pause will continue as CDC advisors gather more information on rare blood clots.
You can sign up here to attend the live event today.
See you there!
Richard Biggs, 20, an evolutionary biology major at the University of Colorado Boulder gets his first dose of the Moderna vaccine from Dr. Laird Wolfe. Biggs is one of the first group of students in a new study to determine if the vaccine can prevent COVID-19 infection and transmission in the student population. CU Boulder students will join 12,000 other college students in the country.
Glenn Asakawa/University of Colorado
Moderna is betting its mRNA technology will lead to a new wave of vaccines for diseases like HIV. Here are the top 5 it's working on beyond COVID-19.
Glenn Asakawa/University of Colorado
- Moderna wants to apply what it learned developing a COVID-19 vaccine to other diseases.
- Insider talked Tuesday with CEO Stephane Bancel, who highlighted five vaccine programs to watch.
- They include RSV, CMV, HIV, influenza, and developing a combination vaccine for multiple diseases.
Here's how far along they are>>
A caretaker helps Joost van der Westhuizen up a ramp on August 28, 2014. The South African rugby player died of ALS in 2017.
Lerato Maduna/Foto24/Gallo Images / Getty Images
Lerato Maduna/Foto24/Gallo Images / Getty Images
A promising ALS drug could soon be available in Europe and Canada, but patients in the US say the FDA is dragging its feet and protecting them 'to death'
- Amylyx Pharmaceuticals has developed a drug that could slow the fatal neurological disease ALS.
- It's set to seek approval this year in Canada and Europe, but the FDA has asked for another trial.
- That means people with ALS in the US will have to wait to get access to the promising treatment.
A German care worker dances with a senior citizen in 2011.
Sean Gallup/Getty Images
Sean Gallup/Getty Images
Biden's infrastructure plan earmarks $400 billion in home-based care for aging Americans - and it could shake up the lucrative home care industry
- Biden's infrastructure plan allocates $400 billion for home care workers, signaling the White House's pro-union shift.
- If realized, his plan could cut into the lucrative home healthcare industry's bottom line.
- Biden's spotlight on caregiving reflects America's aging population, which is poised to remake the healthcare industry by 2030.
More stories we're reading:
- Moderna's CEO shares his strategy to develop a 'world-changing' single vaccine that protects against COVID-19, the flu, and other respiratory illnesses (Insider)
- House committee leaders are pressing HHS to enforce the hospital price transparency rule (InsideHealthPolicy)
- Americans might start getting a 3rd booster shot for Moderna vaccines this year (Insider)
- Wisconsin's supreme court ruled its governor can't limit restaurant capacity without approval from the state legislature (Milwaukee Journal Sentinel)
- America's best work-from-home expert is bracing for turmoil (Insider)
- Lydia